ArticleJournal of cheminformatics2025
Mixture of experts for multitask learning in cardiotoxicity assessment.
Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cardiosim-Tox: an interpretable multitask deep learning QSAR platform with multimodal feature fusion for predicting hERG, Cav1.2, and Nav1.5 blockade risk and potency.Archives of toxicology · 2026Article
- Predicting toxicity and bioactivity of the chemical exposome: a case study for the blood exposome database.Journal of cheminformatics · 2026Article
- Artificial intelligence in cardio-oncology: decoding mechanisms, predicting toxicity, and personalizing cancer therapy.Frontiers in cardiovascular medicine · 2026Review
- Predicting Toxicity and Bioactivity of the Chemical Exposome: A Case Study for the Blood Exposome Database.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In recent years, the integration of Artificial Intelligence and Machine Learning methods with biochemical and biomedical research has revolutionized the field of toxicology, significantly advancing our understanding of the toxicological effects of chemicals on biological systems. Cardiovascular diseases remain the leading global cause of death. The constant exposure to multiple chemicals with potential cardiotoxic effects, including environmental contaminants, pesticides, food additives, and drugs, can significantly contribute to these adverse health outcomes. Traditional methods for assessing chemical hazards and their impact on biological function heavily rely on experimental assays and animal studies, which are often time-consuming, resource-intensive, and limited in scalability. To overcome these limitations in silico methods have emerged as indispensable tools in toxicological research, reducing the need for traditional in vivo testing and conserving valuable resources in terms of time and cost. In this study, Artificial Intelligence methods are used as first-tier components within an Integrated Approach to Testing and Assessment. We explored the potential benefits of using Multitask Neural Networks, where multiple levels of cardiotoxicity information are combined to enhance model performance. Multitask learning, based on specific architectures such as Mixture of Experts (MoE), showed promising results and surpasses the performance of single-task baseline models. When predicting a holdout set, multitask model achieved high performance on twelve different endpoints related to cardiotoxicity defined by Adverse Outcome Pathways Network. The best developed model achieved a balanced accuracy of 78%, a sensitivity of 80%, and a specificity of 76% across all endpoints in the holdout set. SCIENTIFIC CONTRIBUTION: An advanced multitask model was developed to predict cardiotoxicity mechanisms induced by small molecules. The model demonstrates broad mechanistic coverage and achieves performance comparable to, or exceeding, state-of-the-art methods. These results suggest that the model could serve as a valuable first-tier component in advanced New Approach Methodologies for prioritizing chemicals for further testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.